 |
DNAlite Therapeutics
Last updated: August 13, 2024
Mubhij Ahmad, CO-FOUNDER and CEO
USA | Funding: $8.3M (+)
Website: https://www.dnalite.com/
DNAlite Therapeutics committed to bringing the next-generation of drugs to organs protected by mucus barriers. Diseases such as FAP, colorectal cancer, and Crohn's disease are currently treated with complete or partial removal of the colon and/or rectum. Our aim is to prevent, rather than manage the progression of these diseases.
Website: https://www.dnalite.com/
DNAlite Therapeutics committed to bringing the next-generation of drugs to organs protected by mucus barriers. Diseases such as FAP, colorectal cancer, and Crohn's disease are currently treated with complete or partial removal of the colon and/or rectum. Our aim is to prevent, rather than manage the progression of these diseases.
